Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Launched by SUN YAT-SEN UNIVERSITY · Jul 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with unresectable pleural mesothelioma, which is a type of cancer affecting the lining of the lungs. The trial is testing a drug called cadonilimab, which works by helping the body’s immune system fight the cancer, combined with another medication called bevacizumab and standard chemotherapy. The goal is to see if this combination is effective and safe for patients who cannot have surgery to remove their cancer.

To be eligible for this trial, participants must have a confirmed diagnosis of pleural mesothelioma that cannot be surgically removed, and they should not have received any other treatments for advanced disease. Additionally, they should have a good performance status, meaning they are generally able to carry out daily activities. Participants will undergo treatment and regular check-ups to monitor their health and how well the treatment is working. This study is currently recruiting patients aged 65 and older, and it’s important for potential participants to discuss with their doctors whether they meet the criteria and if this trial is a suitable option for them.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • 1. Histologically confirmed pleural malignant mesothelioma not eligible for curative surgery
• • 2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• • 3. No previous systemic anti-tumor treatment for advanced/metastatic disease
• • 4. Measurable disease as per mRECIST v1.1 for assessment of response in malignant pleural mesothelioma.
• • 5. Adequate haematological, renal and liver function.
• Key Exclusion Criteria:
• • 1. Primitive peritoneal, pericardial and tunica vaginalis testis mesothelioma.
• • 2. Active, untreated central nervous system (CNS) metastasis.
• • 3. Use of Chinese herbal medicine or immunomodulatory agents with anti-tumor indications within 14 days prior to the first dose of study treatment.
• • 4. Known active autoimmune diseases.
• • 5. Presence of other uncontrolled serious medical conditions.